Renaissance Capital logo

Sagimet Biosciences Priced, Nasdaq: SGMT

Phase 2 biotech developing a selective FASN inhibitor for NASH and cancers.

Industry: Health Care

Latest Trade: $5.61 +0.19 (+3.5%)

First Day Return: -0.3%

Return from IPO: -66.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH), for which there are no treatments currently approved in the United States or Europe. Denifanstat has been studied in over 600 people to date and we are currently testing it in our FASCINATE-2 Phase 2b trial in NASH. The interim results, which were presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2022, showed statistically significant improvements across key markers of disease in patients treated with denifanstat, including an approximately 34% reduction in liver fat and 67% responder rate (defined as reduction in liver fat by 30% or more) at 26 weeks as compared to baseline. These interim results are consistent with earlier findings from our FASCINATE-1 Phase 2 trial, which achieved its primary endpoint (relative change from baseline in liver fat at 12 weeks) and key secondary endpoint (percentage of subjects with at least a 30% reduction in liver fat at 12 weeks) at the once-daily 50mg dose.
more less
IPO Data
IPO File Date 06/23/2023
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.3
Deal Size ($mm) $85
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/13/2023
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.3
Deal Size ($mm) $85
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Goldman Sachs
TD Cowen
more
Company Data
Headquarters San Mateo, CA, United States
Founded 2006
Employees at IPO 10
Website www.sagimet.com

Sagimet Biosciences (SGMT) Performance